4.5 Article

Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective

期刊

PLATELETS
卷 33, 期 7, 页码 955-963

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/09537104.2021.2019210

关键词

Hemorrhage; inflammation; myeloproliferative neoplasms; platelets; thrombosis

向作者/读者索取更多资源

Classical myeloproliferative neoplasm (MPN) is a clonal disease characterized by abnormal expansion of hematopoietic stem cells. MPN patients are more susceptible to thrombotic events, but antiplatelet therapies may cause bleeding. Platelets play a critical role in the pathogenesis of MPN and optimizing antithrombotic treatment strategies by adjusting the administration of antiplatelet drugs may achieve simultaneous control of thrombosis and bleeding.
Classical myeloproliferative neoplasm (MPN), also known as BCR-ABL-negative MPN, is a clonal disease characterized by abnormal expansion of hematopoietic stem cells. It has been demonstrated that MPN patients are more susceptible to thrombotic events compared to the general population. Therefore, researchers have been exploring the treatment for MPN thrombosis. However, antithrombotic therapies have brought another concern for the clinical management of MPN because they may cause bleeding events. When thrombosis and bleeding, two seemingly contradictory complications, occur in MPN patients at the same time, they will lead to more serious consequences. Therefore, it is a major challenge to achieving the best antithrombotic effect and minimizing bleeding events simultaneously. To date, there has yet been a perfect strategy to meet this challenge and therefore a new treatment method needs to be established. In this article, we describe the mechanism of thrombosis and bleeding events in MPN from the perspective of platelets for the first time. Based on the double-sided role of platelets in MPN, optimal antithrombotic treatment strategies that can simultaneously control thrombosis and bleeding at the same time may be formulated by adjusting the administration time and dosage of antiplatelet drugs. We argue that more attention should be paid to the critical role of platelets in MPN thrombosis and MPN bleeding in the future, so as to better manage adverse vascular events in MPN.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据